|
|
|
| |
Peptide-Affinity Purified Polyclonal Antibody to Syntrophin (alpha 1) |
|
|
| |
|
|
| |
|
| Catalog No: |
IMG-3314 |
| Contents: |
0.1 mg of purified antibody. 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. |
| Isotype: |
Goat Ig |
| Clone: |
N/A |
| Purification: |
Antigen Affinity Chromatography |
| Species: |
Human |
| Predicted React: |
Mouse, Rat |
| Host: |
Goat |
| Application: |
ELISA: >1:32000
Western blot analysis: 0.1-0.5 ug/ml |
| Storage: |
Store at -20°C. |
Recommended
Positive Control: |
human brain or heart |
|
 |
|
|
|
|
|
|
Background
Principal Names – SNTA1; SNT1; TACIP1; dJ1187J4.5; syntrophin, alpha 1 (dystrophin-associated protein A1, 59kDa, acidic component); pro-TGF-alpha cytoplasmic domain-interacting protein 1; dystrophin-associated protein A1, 59kD, acidic component; syntrophin, alpha 1 (dystrophin-associated protein A1, 59kD, acidic component)
Official Gene Symbol - SNTA1
GenBank Accession Number – NP_003089
LocusLink ID - 6640 (human); 20648 (mouse)
Gene Ontology Terms - actin binding; calmodulin binding; calcium ion binding; muscle contraction; membrane; cytoskeleton |
Antigen
Peptide with sequence ASGRRAPRTGLLE, from N Terminus of the protein sequence according to NP_003089. |
Application Notes
An ~60 kDa band is observed in human brain lysates (predicted MW of 58 kDa according to NP_003089). |
Genebank Info (Protein)
NP_003089 |
| |
|
IMG-3314 staining (0.1 µg/ml) of human heart lysate (RIPA buffer, 30µg total protein per lane). Primary incubated for 1 hour. Detected by western blot using chemiluminescence. |
|
|
|
|
|
| - |
 |
|
Reference
1. Fernandez-Larrea J, Merlos-Suarez A, Urena JM, Baselga J, Arribas J. A role for a PDZ protein in the early secretory pathway for the targeting of proTGF-alpha to the cell surface. Mol Cell. 1999 Apr;3(4):423-33. PMID: 10230395
|
|
|
|
Research purposes only.
Not for diagnostic or in vivo use. This product is guaranteed to perform as indicated on the datasheet for one year from the date of purchase.
|
|
|
|
|
